Your session is about to expire
← Back to Search
RSV Vaccine for Respiratory Syncytial Virus
Study Summary
This trial tests a new virus vaccine's safety, tolerability and effectiveness in infants and kids who may have had RSV.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- I have been in close contact with specific groups after getting vaccinated.I have been hospitalized before due to a severe respiratory virus infection.My child is healthy, aged 18-59 months, and I can consent for them.My child is between 6 to 24 months old and I can consent for them.My child is temporarily ineligible due to a short-term condition.I am up to date with all vaccinations suitable for my age.I haven't received immunoglobulin or antibody treatments in the last 6 months.I have had neurological issues after an infection or vaccination.I am either younger than 6 months or older than 60 months.I was born with a major birth defect like cleft palate.I have a lung condition or asthma.I am receiving treatment for a heart condition.I have been hospitalized for a severe infection before.I have a weakened immune system or have had a bone marrow/solid organ transplant.I have a long-term illness.My child was born prematurely and is under 1 year old.I have not received any RSV antibody treatment in the past year.My child is between 6 to 24 months old.I was born before 34 weeks of pregnancy and am now over 1 year old.My growth in height and weight is normal for my age.I have an autoimmune, inflammatory, vascular, or rheumatic condition.My child is between 18 to 59 months old and has tested positive for the study condition.I have had a severe reaction to a vaccine before.I am currently on immunosuppressive therapy, including steroids.I have not received any blood products in the last 6 months.I am scheduled to receive certain vaccines or medications before or after the trial vaccine.
- Group 1: Group 3, children (age 8-24 months), RSV+ or RSV-, Placebo
- Group 2: Group 3, children (age 8-24 months), RSV+ or RSV-, BLB201 10^6 PFU
- Group 3: Group 4, children (age 6-24 months), RSV+ or RSV-, BLB201 10^7 PFU
- Group 4: Group 6, children (age 8-24 months), RSV+ or RSV-, Placebo
- Group 5: Group 6, children (age 8-24 months), RSV+ or RSV-, BLB201 10^7 PFU
- Group 6: Group 4, children (age 8-24 months), RSV+ or RSV-, Placebo
- Group 7: Group 1, infants (age 18-59 months), RSV+, BLB201 10^6 PFU
- Group 8: Group 1, infants (age 18-59 months), RSV+, Placebo
- Group 9: Group 2, infants (age 18-59 months), RSV+, BLB201 10^7 PFU
- Group 10: Group 2, infants (age 18-59 months), RSV+, Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this experiment allow those aged 40 and older to participate?
"This clinical trial allows for participants aged 18-75, with exception to those under the age of 18 and above 65. For these two groups, there are additional studies available."
Are there any opportunities for volunteers to join this clinical experiment?
"The clinicaltrials.gov website reveals that this study has closed its recruitment period, with the original posting taking place on January 23rd 2023 and the last update occurring on December 8th 2022. However, there are still 32 other ongoing trials seeking out potential candidates at present."
Do I meet the requirements to participate in this experiment?
"This clinical trial is admitting 150 persons, ranging in age from 18 to 75 years old, who have a current RSV infection. All participants must also meet the following criteria: Have accepted routine immunizations per ACIP guidelines for their age group as verified by LAR, Display normal growth on WHO chart and possess height/weight above 3rd percentile for age., For infants 6-24 months of age: Sero+ or sero- status with regards to RSV antibody titer assay not more than 30 days prior to vaccination, Healthy children aged 18 months - 60 months whose legal representative has signed informed consent form and agreed to vaccine administration once"
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger